- Tonix Pharmaceuticals (TNXP) takes advantage of the recent moonshot in its stock, selling nearly 3M shares in a secondary priced at $15 each. The underwriters retain an option to buy another 434.8K shares. Assuming no exercise of the greenshoe option, Tonix expects net proceeds of about $40.7M.
- Apparently already with enough cash to see through to the end of the Phase 2b/3 trial for TNX-102 SL for fibromyalgia, the new funds will be used to initiate a trial of the drug for PTSD, and start trials for TNX-201 for tension-type headache.
- Shares off 4% premarket to $15.75
- Press release
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs